Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 23816960

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2013 Sep 20
First author
Sequist LV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2013 Sep 20;31(27):3303-6. doi: 10.1200/JCO.2013.49.8782.
    note
    Source null
    related pmid
    23980079
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2014 Mar 10;32(8):859-63. doi: 10.1200/JCO.2013.52.8794.
    note
    Source null
    related pmid
    24493720
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2014 Mar 10;32(8):864-5. doi: 10.1200/JCO.2013.52.4538.
    note
    Source null
    related pmid
    24493732
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2014 Mar 10;32(8):865. doi: 10.1200/JCO.2013.54.1904.
    note
    Source null
    related pmid
    24493733
    relationship
    Comment in
  5. citation
    J Clin Oncol. 2014 Mar 10;32(8):863-4. doi: 10.1200/JCO.2013.54.1920.
    note
    Source null
    related pmid
    24493734
    relationship
    Comment in
  6. citation
    J Clin Oncol. 2023 Jun 1;41(16):2869-2876. doi: 10.1200/JCO.22.02547.
    note
    Source null
    related pmid
    37235976
    relationship
    Republished in

Authors and identifiers

  1. name
    Sequist LV
    type
    Author
  2. name
    Yang JC
    type
    Author
  3. name
    Yamamoto N
    type
    Author
  4. name
    O'Byrne K
    type
    Author
  5. name
    Hirsh V
    type
    Author
  6. name
    Mok T
    type
    Author
  7. name
    Geater SL
    type
    Author
  8. name
    Orlov S
    type
    Author
  9. name
    Tsai CM
    type
    Author
  10. name
    Boyer M
    type
    Author
  11. name
    Su WC
    type
    Author
  12. name
    Bennouna J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sequist LV
    type
    Author
  2. name
    Yang JC
    type
    Author
  3. name
    Yamamoto N
    type
    Author
  4. name
    O'Byrne K
    type
    Author
  5. name
    Hirsh V
    type
    Author
  6. name
    Mok T
    type
    Author
  7. name
    Geater SL
    type
    Author
  8. name
    Orlov S
    type
    Author
  9. name
    Tsai CM
    type
    Author
  10. name
    Boyer M
    type
    Author
  11. name
    Su WC
    type
    Author
  12. name
    Bennouna J
    type
    Author
bibliography ids
  1. nci-bib-70016b9517eb6137ad7e6d57
book metadata
content sha256
38efac9303a95be4de987512e39ea497594fb772b06a9fb02a61ce0575d50a27
document type
citation
dois
  1. 10.1200/JCO.2012.44.2806
electronic publication date
display
2013 Jul 1
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:23816960
immutable id
pubmed:23816960@38efac9303a95be4de987512e39ea497594fb772b06a9fb02a61ce0575d50a27
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
27
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3327-34
volume
31
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2013 Sep 20;31(27):3303-6. doi: 10.1200/JCO.2013.49.8782.
    note
    Source null
    related pmid
    23980079
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2014 Mar 10;32(8):859-63. doi: 10.1200/JCO.2013.52.8794.
    note
    Source null
    related pmid
    24493720
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2014 Mar 10;32(8):864-5. doi: 10.1200/JCO.2013.52.4538.
    note
    Source null
    related pmid
    24493732
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2014 Mar 10;32(8):865. doi: 10.1200/JCO.2013.54.1904.
    note
    Source null
    related pmid
    24493733
    relationship
    Comment in
  5. citation
    J Clin Oncol. 2014 Mar 10;32(8):863-4. doi: 10.1200/JCO.2013.54.1920.
    note
    Source null
    related pmid
    24493734
    relationship
    Comment in
  6. citation
    J Clin Oncol. 2023 Jun 1;41(16):2869-2876. doi: 10.1200/JCO.22.02547.
    note
    Source null
    related pmid
    37235976
    relationship
    Republished in
outcomes validated
false
pmid
23816960
provenance
batch id
0a08f044391426feb8ef
provider
NCBI PubMed ESummary
record sha256
c416c13b2babb74905cc67e835ab5eb8358d62f91849fe6170456733601cb64d
response sha256
d94e6242343e5962374663e5e5f0191e7b595329228d2e360db95a280e588409
retrieved at
2026-09-09T23:46:57.614689+00:00
publication date
display
2013 Sep 20
precision
day
year
2013
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/23816960/
title
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Preserved source evidence · Not medical advice